Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) is advancing a strategy that integrates three emerging frontiers in cancer drug development: novel DNA damage response (DDR) biology, nanoparticle drug delivery, and artificial intelligence. The company's lead candidate, ONC010, targets PNKP, a DDR target distinct from PARP, and is delivered via a proprietary nanoparticle system. Through its Inka Health subsidiary and the SynoGraph causal AI platform, Onco-Innovations also applies AI to patient stratification, trial design, and evidence generation.
Cancer drug development faces three persistent problems: tumors evolve resistance to therapies, clinical trials are costly and often fail due to difficulty identifying the right patients, and many promising drugs never reach patients because of toxicity or delivery challenges. Onco-Innovations addresses these issues by combining novel biology, advanced drug delivery, and artificial intelligence into a unified development strategy.
The company's focus on PNKP inhibition represents a new approach in the DDR space. While PARP inhibitors have been successful, PNKP is a different target that may offer advantages in certain tumor types. The nanoparticle delivery system is designed to improve drug bioavailability and reduce off-target effects, potentially lowering toxicity. Meanwhile, the SynoGraph causal AI platform aims to identify biomarkers and patient subgroups that are most likely to respond, improving trial efficiency and success rates.
Onco-Innovations is currently advancing ONC010 through IND-enabling studies, manufacturing, and regulatory work. The company believes that integrating these technologies early in development can reduce the high failure rate of oncology drugs and bring more effective treatments to patients faster.
For more information about Onco-Innovations, visit the company’s newsroom at ibn.fm/ONNVF.
InvestorWire, a specialized communications platform, syndicated this press release. For more details, see the terms of use and disclaimers at InvestorWire Disclaimer.
